TY - JOUR
T1 - Progress in ovarian cancer research
T2 - Proceedings of the 5th Biennial Ovarian Cancer Research Symposium
AU - Disis, M. L.
AU - Rivkin, S. E.
AU - Baron, A.
AU - Markman, M.
AU - Connolly, D.
AU - Ueland, F.
AU - Kohn, E.
AU - Trimble, E.
AU - Berek, J. S.
PY - 2006
Y1 - 2006
N2 - Ovarian cancer remains the most lethal gynecological malignancy. The 5th Biennial Symposium overviewed the progress of ovarian cancer research over the last few years. Molecularly based technologies have allowed the identification of multiple biomarkers to aid in ovarian cancer diagnosis and treatment. Furthermore, data analysis systems evaluating the behavior of these markers have been designed. Therapeutic use of ovarian cancer protein markers has been fueled by the development of animal models that more closely simulate the pathogenesis of ovarian cancer, and multiple new therapies are being developed that may have impact against the disease. Finally, the design of clinical trials both for ovarian cancer treatment and prevention are key in advancing the science of ovarian cancer into the clinic. The need for strategies that would optimize patient participation in clinical trials is paramount.
AB - Ovarian cancer remains the most lethal gynecological malignancy. The 5th Biennial Symposium overviewed the progress of ovarian cancer research over the last few years. Molecularly based technologies have allowed the identification of multiple biomarkers to aid in ovarian cancer diagnosis and treatment. Furthermore, data analysis systems evaluating the behavior of these markers have been designed. Therapeutic use of ovarian cancer protein markers has been fueled by the development of animal models that more closely simulate the pathogenesis of ovarian cancer, and multiple new therapies are being developed that may have impact against the disease. Finally, the design of clinical trials both for ovarian cancer treatment and prevention are key in advancing the science of ovarian cancer into the clinic. The need for strategies that would optimize patient participation in clinical trials is paramount.
KW - Cancer
KW - Ovarian
KW - Research
KW - Translational
UR - http://www.scopus.com/inward/record.url?scp=33646052015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646052015&partnerID=8YFLogxK
U2 - 10.1136/ijgc-00009577-200603000-00001
DO - 10.1136/ijgc-00009577-200603000-00001
M3 - Article
C2 - 16681712
AN - SCOPUS:33646052015
SN - 1048-891X
VL - 16
SP - 463
EP - 469
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 2
ER -
